{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:32:53Z","timestamp":1790217173956,"version":"4.1.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,25]],"date-time":"2020-03-25T00:00:00Z","timestamp":1585094400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,25]],"date-time":"2020-03-25T00:00:00Z","timestamp":1585094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Clear cell renal cell carcinoma (ccRCC) is the most common kidney cancer. Prognosis for ccRCC is generally poor since it is largely resistant to chemo- and radiotherapy. Many studies suggested that cancer stem cells\/tumor initiating cells (CSCs\/TICs) are responsible for development of tumor, disease progression, aggressiveness, metastasis and drug resistance. However, tumorigenic potential of CSCs\/TICs isolated from established RCC cell lines \u2013 basic ccRCC research model \u2013 has never been investigated<jats:italic>in vivo<\/jats:italic>. CD105+, CD105\u2212, CD44+ and CD44\u2212 as well as CD44\u2212\/CD105\u2212 CD44+\/CD105+ and CD44\u2212\/CD105+ cells were isolated from Caki-1 RCC cell line, confirming coexistence of multiple subpopulations of stem-related phenotype in stable cell line. Sorted cells were injected subcutaneously into NOD SCID mice and tumor growth was monitored with MRI and PET\/CT. Tumor growth was observed after implantation of CD105+, CD44+, CD44\u2212, CD44\u2212\/CD105+ and CD44\u2212\/CD105\u2212 but not CD105\u2212 or CD44+\/CD105+. Implantation of CD44\u2212\/CD105\u2212 cells induced tumors that were characterized by longer T1 and distinct metabolic pattern than other tumors. All the tumors were characterized by low uptake of [18F]FDG. CD105+ and CD44\u2212 tumors expresses Nanog and Oct-4, while CD44\u2212 tumors additionally expressed endothelial cell marker - CD31.<\/jats:p>","DOI":"10.1038\/s41598-020-62205-6","type":"journal-article","created":{"date-parts":[[2020,3,25]],"date-time":"2020-03-25T11:03:32Z","timestamp":1585134212000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Renal carcinoma CD105\u2212\/CD44\u2212 cells display stem-like properties in vitro and form aggressive tumors in vivo"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5755-3608","authenticated-orcid":false,"given":"M.","family":"Fiedorowicz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. I.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Strzemecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Orze\u0142","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"We\u0142niak-Kami\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Sobiborowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Wieteska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Rogulski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Cheda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Wargocka-Matuszewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3812-3917","authenticated-orcid":false,"given":"K.","family":"Kilian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Szczylik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2107-3810","authenticated-orcid":false,"given":"A. M.","family":"Czarnecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,25]]},"reference":[{"key":"62205_CR1","doi-asserted-by":"publisher","first-page":"17009","DOI":"10.1038\/nrdp.2017.9","volume":"3","author":"JJ Hsieh","year":"2017","unstructured":"Hsieh, J. J. et al. Renal cell carcinoma. Nature Reviews Disease Primers 3, 17009, https:\/\/doi.org\/10.1038\/nrdp.2017.9 (2017).","journal-title":"Nature Reviews Disease Primers"},{"key":"62205_CR2","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2174\/1574362409666140206222251","volume":"8","author":"AM Czarnecka","year":"2013","unstructured":"Czarnecka, A. M. & Szczylik, C. Renal Cell Carcinoma Cancer Stem Cells as Therapeutic Targets. Current signal transduction therapy 8, 203\u2013209 (2013).","journal-title":"Current signal transduction therapy"},{"key":"62205_CR3","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.2144\/03356ss06","volume":"35","author":"TE Meyerrose","year":"2003","unstructured":"Meyerrose, T. E., Herrbrich, P., Hess, D. A. & Nolta, J. A. Immune-deficient mouse models for analysis of human stem cells. BioTechniques 35, 1262\u20131272 (2003).","journal-title":"BioTechniques"},{"key":"62205_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/srep25220","volume":"6","author":"C Gedye","year":"2016","unstructured":"Gedye, C. et al. Cancer stem cells are underestimated by standard experimental methods in clear cell renal cell carcinoma. Scientific reports 6, 25220, https:\/\/doi.org\/10.1038\/srep25220 (2016).","journal-title":"Scientific reports"},{"key":"62205_CR5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/jso.23069","volume":"106","author":"BA Grotenhuis","year":"2012","unstructured":"Grotenhuis, B. A., Wijnhoven, B. P. & van Lanschot, J. J. Cancer stem cells and their potential implications for the treatment of solid tumors. Journal of surgical oncology 106, 209\u2013215, https:\/\/doi.org\/10.1002\/jso.23069 (2012).","journal-title":"Journal of surgical oncology"},{"key":"62205_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.bbcan.2013.10.001","volume":"1845","author":"M Buczek","year":"2014","unstructured":"Buczek, M., Escudier, B., Bartnik, E., Szczylik, C. & Czarnecka, A. M. Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: from the patient's bed to molecular mechanisms. Biochimica et biophysica acta 1845, 31\u201341, https:\/\/doi.org\/10.1016\/j.bbcan.2013.10.001 (2014).","journal-title":"Biochimica et biophysica acta"},{"key":"62205_CR7","doi-asserted-by":"publisher","first-page":"218","DOI":"10.2174\/1574362409666140206223014","volume":"8","author":"ZF Bielecka","year":"2014","unstructured":"Bielecka, Z. F., Czarnecka, A. M., Solarek, W., Kornakiewicz, A. & Szczylik, C. Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC). Current signal transduction therapy 8, 218\u2013228, https:\/\/doi.org\/10.2174\/1574362409666140206223014 (2014).","journal-title":"Current signal transduction therapy"},{"key":"62205_CR8","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13578-017-0197-8","volume":"7","author":"ZF Bielecka","year":"2017","unstructured":"Bielecka, Z. F. et al. Hypoxic 3D in vitro culture models reveal distinct resistance processes to TKIs in renal cancer cells. Cell Biosci 7, 71, https:\/\/doi.org\/10.1186\/s13578-017-0197-8 (2017).","journal-title":"Cell Biosci"},{"key":"62205_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-016-0565-8","volume":"15","author":"KK Brodaczewska","year":"2016","unstructured":"Brodaczewska, K. K., Szczylik, C., Fiedorowicz, M., Porta, C. & Czarnecka, A. M. Choosing the right cell line for renal cell cancer research. Mol Cancer 15, 83, https:\/\/doi.org\/10.1186\/s12943-016-0565-8 (2016).","journal-title":"Mol Cancer"},{"key":"62205_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-9-180","volume":"9","author":"BG Debeb","year":"2010","unstructured":"Debeb, B. G. et al. Characterizing cancer cells with cancer stem cell-like features in 293T human embryonic kidney cells. Mol Cancer 9, 180, https:\/\/doi.org\/10.1186\/1476-4598-9-180 (2010).","journal-title":"Mol Cancer"},{"key":"62205_CR11","doi-asserted-by":"publisher","first-page":"e75463","DOI":"10.1371\/journal.pone.0075463","volume":"8","author":"K Ueda","year":"2013","unstructured":"Ueda, K. et al. Aldehyde dehydrogenase 1 identifies cells with cancer stem cell-like properties in a human renal cell carcinoma cell line. PloS one 8, e75463, https:\/\/doi.org\/10.1371\/journal.pone.0075463 (2013).","journal-title":"PloS one"},{"key":"62205_CR12","doi-asserted-by":"publisher","first-page":"e0165718","DOI":"10.1371\/journal.pone.0165718","volume":"11","author":"MI Khan","year":"2016","unstructured":"Khan, M. I. et al. Comparative Gene Expression Profiling of Primary and Metastatic Renal Cell Carcinoma Stem Cell-Like Cancer Cells. PLoS One 11, e0165718, https:\/\/doi.org\/10.1371\/journal.pone.0165718 (2016).","journal-title":"PLoS One"},{"key":"62205_CR13","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1096\/fj.08-102590","volume":"22","author":"B Bussolati","year":"2008","unstructured":"Bussolati, B., Bruno, S., Grange, C., Ferrando, U. & Camussi, G. Identification of a tumor-initiating stem cell population in human renal carcinomas. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 22, 3696\u20133705, https:\/\/doi.org\/10.1096\/fj.08-102590 (2008).","journal-title":"FASEB journal: official publication of the Federation of American Societies for Experimental Biology"},{"key":"62205_CR14","first-page":"1","volume":"112","author":"A Czarnecka","year":"2013","unstructured":"Czarnecka, A., Matak, D., Solarek, W., Khan, M. & Szczylik, C. Hypoxia response regulates clear cell renal cell carcinoma tumor initiating cells. BJU international 112, 1\u201317 (2013).","journal-title":"BJU international"},{"key":"62205_CR15","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.2353\/ajpath.2006.060498","volume":"169","author":"S Bruno","year":"2006","unstructured":"Bruno, S. et al. CD133+ renal progenitor cells contribute to tumor angiogenesis. The American journal of pathology 169, 2223\u20132235, https:\/\/doi.org\/10.2353\/ajpath.2006.060498 (2006).","journal-title":"The American journal of pathology"},{"key":"62205_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1464-410X.2012.11574.x","volume":"110","author":"AM Czarnecka","year":"2012","unstructured":"Czarnecka, A. M. & Solarek, W. The activity of tyrosine kinase inhibitors on clear cell renal cell carcinoma tumor initiating cells in hypoxic microenvironment. BJU Intnernational 110, 1\u201320, https:\/\/doi.org\/10.1111\/j.1464-410X.2012.11574.x (2012).","journal-title":"BJU Intnernational"},{"key":"62205_CR17","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1002\/stem.1407","volume":"31","author":"M Gassenmaier","year":"2013","unstructured":"Gassenmaier, M. et al. CXC chemokine receptor 4 is essential for maintenance of renal cell carcinoma-initiating cells and predicts metastasis. Stem cells (Dayton, Ohio) 31, 1467\u20131476, https:\/\/doi.org\/10.1002\/stem.1407 (2013).","journal-title":"Stem cells (Dayton, Ohio)"},{"key":"62205_CR18","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13287-015-0177-z","volume":"6","author":"MI Khan","year":"2015","unstructured":"Khan, M. I. et al. Current approaches in identification and isolation of human renal cell carcinoma cancer stem cells. Stem Cell Res Ther 6, 178, https:\/\/doi.org\/10.1186\/s13287-015-0177-z (2015).","journal-title":"Stem Cell Res Ther"},{"key":"62205_CR19","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2174\/1574362409666140206222607","volume":"8","author":"D Matak","year":"2013","unstructured":"Matak, D., Szymanski, L., Czarnecka, A. M., Bartnik, E. & Szczylik, C. Clear Cell Renal Cell Cancer Tumor-Propagating Cells: Molecular Characteristics. Current signal transduction therapy 8, 229\u2013239 (2013).","journal-title":"Current signal transduction therapy"},{"key":"62205_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2985-7","volume":"17","author":"D Matak","year":"2017","unstructured":"Matak, D. et al. Functional significance of CD105\u2212positive cells in papillary renal cell carcinoma. BMC Cancer 17, 21, https:\/\/doi.org\/10.1186\/s12885-016-2985-7 (2017).","journal-title":"BMC Cancer"},{"key":"62205_CR21","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s10616-017-0181-5","volume":"70","author":"KM Krawczyk","year":"2018","unstructured":"Krawczyk, K. M. et al. Culture in embryonic kidney serum and xeno-free media as renal cell carcinoma and renal cell carcinoma cancer stem cells research model. Cytotechnology 70, 761\u2013782, https:\/\/doi.org\/10.1007\/s10616-017-0181-5 (2018).","journal-title":"Cytotechnology"},{"key":"62205_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/cjp2.91","volume":"4","author":"C Corro","year":"2018","unstructured":"Corro, C. & Moch, H. Biomarker discovery for renal cancer stem cells. J Pathol Clin Res 4, 3\u201318, https:\/\/doi.org\/10.1002\/cjp2.91 (2018).","journal-title":"J Pathol Clin Res"},{"key":"62205_CR23","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.3892\/ol.2013.1270","volume":"5","author":"J Lu","year":"2013","unstructured":"Lu, J. et al. Biological characteristics of Rh123 stem-like cells in a side population of 786-O renal carcinoma cells. Oncology letters 5, 1903\u20131908, https:\/\/doi.org\/10.3892\/ol.2013.1270 (2013).","journal-title":"Oncology letters"},{"key":"62205_CR24","doi-asserted-by":"publisher","first-page":"e68293","DOI":"10.1371\/journal.pone.0068293","volume":"8","author":"B Huang","year":"2013","unstructured":"Huang, B. et al. Cancer stem cell-like side population cells in clear cell renal cell carcinoma cell line 769P. PloS one 8, e68293, https:\/\/doi.org\/10.1371\/journal.pone.0068293 (2013).","journal-title":"PloS one"},{"key":"62205_CR25","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1158\/0008-5472.CAN-11-3062","volume":"72","author":"S Nishizawa","year":"2012","unstructured":"Nishizawa, S. et al. HSP DNAJB8 controls tumor-initiating ability in renal cancer stem-like cells. Cancer research 72, 2844\u20132854, https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-3062 (2012).","journal-title":"Cancer research"},{"key":"62205_CR26","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1089\/scd.2008.0302","volume":"18","author":"JE Oates","year":"2009","unstructured":"Oates, J. E. et al. Hoechst 33342 side population identification is a conserved and unified mechanism in urological cancers. Stem Cells Dev 18, 1515\u20131522, https:\/\/doi.org\/10.1089\/scd.2008.0302 (2009).","journal-title":"Stem Cells Dev"},{"key":"62205_CR27","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1039\/c0an00574f","volume":"135","author":"C Hughes","year":"2010","unstructured":"Hughes, C. et al. SR-FTIR spectroscopy of renal epithelial carcinoma side population cells displaying stem cell-like characteristics. The Analyst 135, 3133\u20133141, https:\/\/doi.org\/10.1039\/c0an00574f (2010).","journal-title":"The Analyst"},{"key":"62205_CR28","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.stemcr.2017.07.009","volume":"9","author":"J Hu","year":"2017","unstructured":"Hu, J. et al. Endoglin Is Essential for the Maintenance of Self-Renewal and Chemoresistance in Renal Cancer Stem Cells. Stem Cell Reports 9, 464\u2013477, https:\/\/doi.org\/10.1016\/j.stemcr.2017.07.009 (2017).","journal-title":"Stem Cell Reports"},{"key":"62205_CR29","doi-asserted-by":"publisher","first-page":"4499","DOI":"10.3892\/etm.2019.7493","volume":"17","author":"D Shi","year":"2019","unstructured":"Shi, D. et al. Expression and clinical value of CD105 in renal cell carcinoma based on data mining in The Cancer Genome Atlas. Exp Ther Med 17, 4499\u20134505, https:\/\/doi.org\/10.3892\/etm.2019.7493 (2019).","journal-title":"Exp Ther Med"},{"key":"62205_CR30","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.3892\/ol.2018.7871","volume":"15","author":"X Yang","year":"2018","unstructured":"Yang, X. et al. Expression of CK19, CD105 and CD146 are associated with early metastasis in patients with renal cell carcinoma. Oncology letters 15, 4229\u20134234, https:\/\/doi.org\/10.3892\/ol.2018.7871 (2018).","journal-title":"Oncology letters"},{"key":"62205_CR31","doi-asserted-by":"publisher","first-page":"9060152","DOI":"10.1155\/2019\/9060152","volume":"2019","author":"J Hu","year":"2019","unstructured":"Hu, J. et al. Cancer Stem Cell Marker Endoglin (CD105) Induces Epithelial Mesenchymal Transition (EMT) but Not Metastasis in Clear Cell Renal Cell Carcinoma. Stem Cells Int 2019, 9060152, https:\/\/doi.org\/10.1155\/2019\/9060152 (2019).","journal-title":"Stem Cells Int"},{"issue":"5","key":"62205_CR32","doi-asserted-by":"publisher","first-page":"646","DOI":"10.3390\/jcm8050646","volume":"8","author":"Gray W. Pearson","year":"2019","unstructured":"Pearson, G. W. Control of Invasion by Epithelial-to-Mesenchymal Transition Programs during Metastasis. Journal of clinical medicine 8, https:\/\/doi.org\/10.3390\/jcm8050646 (2019).","journal-title":"Journal of Clinical Medicine"},{"issue":"1","key":"62205_CR33","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s10616-018-0273-x","volume":"71","author":"Kamila Maliszewska-Olejniczak","year":"2018","unstructured":"Maliszewska-Olejniczak, K. et al. Development of extracellular matrix supported 3D culture of renal cancer cells and renal cancer stem cells. Cytotechnology, https:\/\/doi.org\/10.1007\/s10616-018-0273-x (2018).","journal-title":"Cytotechnology"},{"key":"62205_CR34","doi-asserted-by":"publisher","first-page":"5567","DOI":"10.18632\/oncotarget.1901","volume":"6","author":"Z Lichner","year":"2015","unstructured":"Lichner, Z. et al. miR-17 inhibition enhances the formation of kidney cancer spheres with stem cell\/ tumor initiating cell properties. Oncotarget 6, 5567\u20135581, https:\/\/doi.org\/10.18632\/oncotarget.1901 (2015).","journal-title":"Oncotarget"},{"key":"62205_CR35","doi-asserted-by":"publisher","first-page":"821","DOI":"10.3233\/CBM-170755","volume":"21","author":"L Saeednejad Zanjani","year":"2018","unstructured":"Saeednejad Zanjani, L. et al. Expression of CD105 cancer stem cell marker in three subtypes of renal cell carcinoma. Cancer Biomark 21, 821\u2013837, https:\/\/doi.org\/10.3233\/CBM-170755 (2018).","journal-title":"Cancer Biomark"},{"key":"62205_CR36","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1097\/01.ASN.0000115703.30835.96","volume":"15","author":"KM Rouschop","year":"2004","unstructured":"Rouschop, K. M. et al. CD44 deficiency increases tubular damage but reduces renal fibrosis in obstructive nephropathy. Journal of the American Society of Nephrology: JASN 15, 674\u2013686 (2004).","journal-title":"Journal of the American Society of Nephrology: JASN"},{"key":"62205_CR37","doi-asserted-by":"publisher","first-page":"R247","DOI":"10.1152\/ajpregu.2000.278.1.R247","volume":"278","author":"AJ Lewington","year":"2000","unstructured":"Lewington, A. J., Padanilam, B. J. & Martin, D. R. & Hammerman, M. R. Expression of CD44 in kidney after acute ischemic injury in rats. Am J Physiol Regul Integr Comp Physiol 278, R247\u2013254, https:\/\/doi.org\/10.1152\/ajpregu.2000.278.1.R247 (2000).","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"62205_CR38","doi-asserted-by":"publisher","first-page":"967","DOI":"10.3109\/0886022X.2013.808955","volume":"35","author":"D Fanni","year":"2013","unstructured":"Fanni, D. et al. CD44 immunoreactivity in the developing human kidney: a marker of renal progenitor stem cells? Ren Fail 35, 967\u2013970, https:\/\/doi.org\/10.3109\/0886022X.2013.808955 (2013).","journal-title":"Ren Fail"},{"key":"62205_CR39","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/sj.ki.5002398","volume":"72","author":"R Poulsom","year":"2007","unstructured":"Poulsom, R. CD44 and hyaluronan help mesenchymal stem cells move to a neighborhood in need of regeneration. Kidney Int 72, 389\u2013390, https:\/\/doi.org\/10.1038\/sj.ki.5002398 (2007).","journal-title":"Kidney Int"},{"key":"62205_CR40","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.2147\/OTT.S96535","volume":"9","author":"HJ Zhang","year":"2016","unstructured":"Zhang, H. J. et al. Twist2 promotes kidney cancer cell proliferation and invasion by regulating ITGA6 and CD44 expression in the ECM-receptor interaction pathway. Onco Targets Ther 9, 1801\u20131812, https:\/\/doi.org\/10.2147\/OTT.S96535 (2016).","journal-title":"Onco Targets Ther"},{"key":"62205_CR41","doi-asserted-by":"publisher","first-page":"e44078","DOI":"10.1371\/journal.pone.0044078","volume":"7","author":"B Krishnamachary","year":"2012","unstructured":"Krishnamachary, B. et al. Hypoxia regulates CD44 and its variant isoforms through HIF-1alpha in triple negative breast cancer. PLoS One 7, e44078, https:\/\/doi.org\/10.1371\/journal.pone.0044078 (2012).","journal-title":"PLoS One"},{"key":"62205_CR42","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/bjc.2015.338","volume":"113","author":"C Micucci","year":"2015","unstructured":"Micucci, C., Matacchione, G., Valli, D., Orciari, S. & Catalano, A. HIF2alpha is involved in the expansion of CXCR4-positive cancer stem-like cells in renal cell carcinoma. Br J Cancer 113, 1178\u20131185, https:\/\/doi.org\/10.1038\/bjc.2015.338 (2015).","journal-title":"Br J Cancer"},{"key":"62205_CR43","unstructured":"Gutteridge, R. J. Caveolin-1 is a modulator of clonogenicityin Renal Cell Carcinoma, Cardiff University, (2016)."},{"key":"62205_CR44","first-page":"4532","volume":"54","author":"M Korhonen","year":"1994","unstructured":"Korhonen, M., Sariola, H., Gould, V. E., Kangas, L. & Virtanen, I. Integrins and laminins in human renal carcinoma cells and tumors grown in nude mice. Cancer research 54, 4532\u20134538 (1994).","journal-title":"Cancer research"},{"key":"62205_CR45","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/neuonc\/now147","volume":"19","author":"J Ziegler","year":"2017","unstructured":"Ziegler, J. et al. ELTD1, an effective anti-angiogenic target for gliomas: preclinical assessment in mouse GL261 and human G55 xenograft glioma models. Neuro-oncology 19, 175\u2013185, https:\/\/doi.org\/10.1093\/neuonc\/now147 (2017).","journal-title":"Neuro-oncology"},{"key":"62205_CR46","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1002\/mrm.1230","volume":"46","author":"H Kobayashi","year":"2001","unstructured":"Kobayashi, H. et al. 3D MR angiography of intratumoral vasculature using a novel macromolecular MR contrast agent. Magnet Reson Med 46, 579\u2013585, https:\/\/doi.org\/10.1002\/mrm.1230 (2001).","journal-title":"Magnet Reson Med"},{"key":"62205_CR47","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/jmri.10318","volume":"18","author":"C Fink","year":"2003","unstructured":"Fink, C. et al. High-resolution three-dimensional MR angiography of rodent tumors: morphologic characterization of intratumoral vasculature. Journal of magnetic resonance imaging: JMRI 18, 59\u201365, https:\/\/doi.org\/10.1002\/jmri.10318 (2003).","journal-title":"Journal of magnetic resonance imaging: JMRI"},{"key":"62205_CR48","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00062-011-0113-2","volume":"22","author":"G Figueiredo","year":"2012","unstructured":"Figueiredo, G. et al. Comparison of digital subtraction angiography, micro-computed tomography angiography and magnetic resonance angiography in the assessment of the cerebrovascular system in live mice. Clinical neuroradiology 22, 21\u201328, https:\/\/doi.org\/10.1007\/s00062-011-0113-2 (2012).","journal-title":"Clinical neuroradiology"},{"key":"62205_CR49","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1148\/radiol.2521081059","volume":"251","author":"R Schor-Bardach","year":"2009","unstructured":"Schor-Bardach, R. et al. Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model? Radiology 251, 731\u2013742, https:\/\/doi.org\/10.1148\/radiol.2521081059 (2009).","journal-title":"Radiology"},{"key":"62205_CR50","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1038\/bjc.1995.93","volume":"71","author":"I Jakobsen","year":"1995","unstructured":"Jakobsen, I., Kaalhus, O., Lyng, H. & Rofstad, E. K. Detection of necrosis in human tumour xenografts by proton magnetic resonance imaging. Br J Cancer 71, 456\u2013461, https:\/\/doi.org\/10.1038\/bjc.1995.93 (1995).","journal-title":"Br J Cancer"},{"key":"62205_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-88","volume":"14","author":"C Weidensteiner","year":"2014","unstructured":"Weidensteiner, C. et al. Tumour T1 changes in vivo are highly predictive of response to chemotherapy and reflect the number of viable tumour cells\u2013a preclinical MR study in mice. BMC cancer 14, 88, https:\/\/doi.org\/10.1186\/1471-2407-14-88 (2014).","journal-title":"BMC cancer"},{"key":"62205_CR52","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/09553009414550451","volume":"65","author":"EK Rofstad","year":"1994","unstructured":"Rofstad, E. K. et al. Magnetic resonance imaging of human melanoma xenografts in vivo: proton spin-lattice and spin-spin relaxation times versus fractional tumour water content and fraction of necrotic tumour tissue. International journal of radiation biology 65, 387\u2013401 (1994).","journal-title":"International journal of radiation biology"},{"key":"62205_CR53","doi-asserted-by":"publisher","unstructured":"Sonkar, K. et al. Focus on the glycerophosphocholine pathway in choline phospholipid metabolism of cancer. NMR Biomed, e4112, https:\/\/doi.org\/10.1002\/nbm.4112 (2019).","DOI":"10.1002\/nbm.4112"},{"issue":"4","key":"62205_CR54","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/jmri.26700","volume":"50","author":"Reza Fardanesh","year":"2019","unstructured":"Fardanesh, R. et al. Proton MR spectroscopy in the breast: Technical innovations and clinical applications. Journal of magnetic resonance imaging: JMRI, https:\/\/doi.org\/10.1002\/jmri.26700 (2019).","journal-title":"Journal of Magnetic Resonance Imaging"},{"key":"62205_CR55","doi-asserted-by":"crossref","first-page":"94","DOI":"10.59566\/IJBS.2012.8094","volume":"8","author":"F S\u00fcllentrop","year":"2012","unstructured":"S\u00fcllentrop, F., Hahn, J. & Moka, D. In Vitro and In Vivo (1)H-MR Spectroscopic Examination of the Renal Cell Carcinoma. International journal of biomedical science: IJBS 8, 94\u2013108 (2012).","journal-title":"International journal of biomedical science: IJBS"},{"key":"62205_CR56","first-page":"3195","volume":"27","author":"V Righi","year":"2007","unstructured":"Righi, V. et al. Ex vivo HR-MAS magnetic resonance spectroscopy of normal and malignant human renal tissues. Anticancer research 27, 3195\u20133204 (2007).","journal-title":"Anticancer research"},{"key":"62205_CR57","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00345-014-1272-y","volume":"33","author":"S Sevcenco","year":"2015","unstructured":"Sevcenco, S. et al. Diagnosis of renal tumors by in vivo proton magnetic resonance spectroscopy. World J Urol 33, 17\u201323, https:\/\/doi.org\/10.1007\/s00345-014-1272-y (2015).","journal-title":"World J Urol"},{"key":"62205_CR58","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/bjc.1993.12","volume":"67","author":"T Kobayashi","year":"1993","unstructured":"Kobayashi, T. et al. Sulfolipids and glycolipid sulfotransferase activities in human renal cell carcinoma cells. Br J Cancer 67, 76\u201380, https:\/\/doi.org\/10.1038\/bjc.1993.12 (1993).","journal-title":"Br J Cancer"},{"key":"62205_CR59","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1053\/j.semnuclmed.2012.02.002","volume":"42","author":"AH Khandani","year":"2012","unstructured":"Khandani, A. H. & Rathmell, W. K. Positron emission tomography in renal cell carcinoma: an imaging biomarker in development. Seminars in nuclear medicine 42, 221\u2013230, https:\/\/doi.org\/10.1053\/j.semnuclmed.2012.02.002 (2012).","journal-title":"Seminars in nuclear medicine"},{"key":"62205_CR60","doi-asserted-by":"publisher","DOI":"10.1007\/s11934-019-0932-2","volume":"20","author":"V Karivedu","year":"2019","unstructured":"Karivedu, V., Jain, A. L., Eluvathingal, T. J. & Sidana, A. Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma. Current urology reports 20, 56, https:\/\/doi.org\/10.1007\/s11934-019-0932-2 (2019).","journal-title":"Current urology reports"},{"key":"62205_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5510-y","volume":"19","author":"T Tabei","year":"2019","unstructured":"Tabei, T. et al. Early assessment with (18)F-2-fluoro-2-deoxyglucose positron emission tomography\/computed tomography to predict short-term outcome in clear cell renal carcinoma treated with nivolumab. BMC cancer 19, 298, https:\/\/doi.org\/10.1186\/s12885-019-5510-y (2019).","journal-title":"BMC cancer"},{"key":"62205_CR62","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1007\/s00259-019-04358-9","volume":"46","author":"SR Verhoeff","year":"2019","unstructured":"Verhoeff, S. R. et al. Lesion detection by [(89)Zr]Zr-DFO-girentuximab and [(18)F]FDG-PET\/CT in patients with newly diagnosed metastatic renal cell carcinoma. European journal of nuclear medicine and molecular imaging 46, 1931\u20131939, https:\/\/doi.org\/10.1007\/s00259-019-04358-9 (2019).","journal-title":"European journal of nuclear medicine and molecular imaging"},{"key":"62205_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7150\/jca.33442","volume":"11","author":"X Wang","year":"2020","unstructured":"Wang, X. et al. Prognostic Values of TIGAR Expression and (18)F-FDG PET\/CT in Clear Cell Renal Cell Carcinoma. Journal of Cancer 11, 1\u20138, https:\/\/doi.org\/10.7150\/jca.33442 (2020).","journal-title":"Journal of Cancer"},{"key":"62205_CR64","doi-asserted-by":"publisher","unstructured":"Zhu, S. et al. Differential diagnostic ability of 18F-FDG PET\/CT radiomics features between renal cell carcinoma and renal lymphoma. The quarterly journal of nuclear medicine and molecular imaging: official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the So, https:\/\/doi.org\/10.23736\/s1824-4785.19.03137-6 (2019).","DOI":"10.23736\/s1824-4785.19.03137-6"},{"key":"62205_CR65","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/cco.0000000000000518","volume":"31","author":"L Lindenberg","year":"2019","unstructured":"Lindenberg, L., Mena, E., Choyke, P. L. & Bouchelouche, K. PET imaging in renal cancer. Current opinion in oncology 31, 216\u2013221, https:\/\/doi.org\/10.1097\/cco.0000000000000518 (2019).","journal-title":"Current opinion in oncology"},{"key":"62205_CR66","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.juro.2013.04.121","volume":"190","author":"SM Donat","year":"2013","unstructured":"Donat, S. M. et al. Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline. The Journal of urology 190, 407\u2013416, https:\/\/doi.org\/10.1016\/j.juro.2013.04.121 (2013).","journal-title":"The Journal of urology"},{"key":"62205_CR67","doi-asserted-by":"publisher","first-page":"v58","DOI":"10.1093\/annonc\/mdw328","volume":"27","author":"B Escudier","year":"2016","unstructured":"Escudier, B. et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 27, v58\u2013v68, https:\/\/doi.org\/10.1093\/annonc\/mdw328 (2016).","journal-title":"Ann Oncol"},{"key":"62205_CR68","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.eururo.2019.02.011","volume":"75","author":"B Ljungberg","year":"2019","unstructured":"Ljungberg, B. et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. European urology 75, 799\u2013810, https:\/\/doi.org\/10.1016\/j.eururo.2019.02.011 (2019).","journal-title":"European urology"},{"key":"62205_CR69","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1102\/1470-7330.2012.0042","volume":"12","author":"HY Wang","year":"2012","unstructured":"Wang, H. Y. et al. Meta-analysis of the diagnostic performance of [18F]FDG-PET and PET\/CT in renal cell carcinoma. Cancer imaging: the official publication of the International Cancer Imaging Society 12, 464\u2013474, https:\/\/doi.org\/10.1102\/1470-7330.2012.0042 (2012).","journal-title":"Cancer imaging: the official publication of the International Cancer Imaging Society"},{"key":"62205_CR70","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s00280-017-3275-z","volume":"79","author":"H Ito","year":"2017","unstructured":"Ito, H. et al. One-month assessment of renal cell carcinoma treated by everolimus using FDG PET\/CT predicts progression-free and overall survival. Cancer chemotherapy and pharmacology 79, 855\u2013861, https:\/\/doi.org\/10.1007\/s00280-017-3275-z (2017).","journal-title":"Cancer chemotherapy and pharmacology"},{"key":"62205_CR71","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1967\/s002449910067","volume":"16","author":"Z Nakhoda","year":"2013","unstructured":"Nakhoda, Z., Torigian, D. A., Saboury, B., Hofheinz, F. & Alavi, A. Assessment of the diagnostic performance of (18)F-FDG-PET\/CT for detection and characterization of solid renal malignancies. Hellenic journal of nuclear medicine 16, 19\u201324, https:\/\/doi.org\/10.1967\/s002449910067 (2013).","journal-title":"Hellenic journal of nuclear medicine"},{"key":"62205_CR72","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/MNM.0b013e3283442e3b","volume":"32","author":"T Ozulker","year":"2011","unstructured":"Ozulker, T., Ozulker, F., Ozbek, E. & Ozpacaci, T. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography\/computed tomography in the evaluation of indeterminate renal masses. Nuclear medicine communications 32, 265\u2013272, https:\/\/doi.org\/10.1097\/MNM.0b013e3283442e3b (2011).","journal-title":"Nuclear medicine communications"},{"key":"62205_CR73","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1097\/MNM.0b013e3283561837","volume":"33","author":"AH Khandani","year":"2012","unstructured":"Khandani, A. H., Cowey, C. L., Moore, D. T., Gohil, H. & Rathmell, W. K. Primary renal cell carcinoma: relationship between 18F-FDG uptake and response to neoadjuvant sorafenib. Nuclear medicine communications 33, 967\u2013973, https:\/\/doi.org\/10.1097\/MNM.0b013e3283561837 (2012).","journal-title":"Nuclear medicine communications"},{"key":"62205_CR74","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.1200\/jco.2003.04.073","volume":"21","author":"NS Majhail","year":"2003","unstructured":"Majhail, N. S. et al. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 21, 3995\u20134000, https:\/\/doi.org\/10.1200\/jco.2003.04.073 (2003).","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"62205_CR75","doi-asserted-by":"publisher","first-page":"55230","DOI":"10.18632\/oncotarget.19420","volume":"8","author":"K Ishibashi","year":"2017","unstructured":"Ishibashi, K. et al. Overriding TKI resistance of renal cell carcinoma by combination therapy with IL-6 receptor blockade. Oncotarget 8, 55230\u201355245, https:\/\/doi.org\/10.18632\/oncotarget.19420 (2017).","journal-title":"Oncotarget"},{"key":"62205_CR76","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1089\/108497804323071922","volume":"19","author":"A Brouwers","year":"2004","unstructured":"Brouwers, A. et al. PET radioimmunoscintigraphy of renal cell cancer using 89Zr-labeled cG250 monoclonal antibody in nude rats. Cancer biotherapy & radiopharmaceuticals 19, 155\u2013163, https:\/\/doi.org\/10.1089\/108497804323071922 (2004).","journal-title":"Cancer biotherapy & radiopharmaceuticals"},{"key":"62205_CR77","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4496-1","volume":"18","author":"MI Khan","year":"2018","unstructured":"Khan, M. I. et al. Involvement of the CB2 cannabinoid receptor in cell growth inhibition and G0\/G1 cell cycle arrest via the cannabinoid agonist WIN 55,212-2 in renal cell carcinoma. BMC cancer 18, 583, https:\/\/doi.org\/10.1186\/s12885-018-4496-1 (2018).","journal-title":"BMC cancer"},{"key":"62205_CR78","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nprot.2007.25","volume":"2","author":"CL Morton","year":"2007","unstructured":"Morton, C. L. & Houghton, P. J. Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc 2, 247\u2013250, https:\/\/doi.org\/10.1038\/nprot.2007.25 (2007).","journal-title":"Nat Protoc"},{"key":"62205_CR79","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s00432-014-1883-0","volume":"141","author":"L Wang","year":"2015","unstructured":"Wang, L., Park, P., La Marca, F., Than, K. D. & Lin, C. Y. BMP-2 inhibits tumor-initiating ability in human renal cancer stem cells and induces bone formation. Journal of cancer research and clinical oncology 141, 1013\u20131024, https:\/\/doi.org\/10.1007\/s00432-014-1883-0 (2015).","journal-title":"Journal of cancer research and clinical oncology"},{"key":"62205_CR80","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.trsl.2015.02.001","volume":"166","author":"C Bernardo","year":"2015","unstructured":"Bernardo, C., Costa, C., Sousa, N., Amado, F. & Santos, L. Patient-derived bladder cancer xenografts: a systematic review. Translational research: the journal of laboratory and clinical medicine 166, 324\u2013331, https:\/\/doi.org\/10.1016\/j.trsl.2015.02.001 (2015).","journal-title":"Translational research: the journal of laboratory and clinical medicine"},{"key":"62205_CR81","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/mrm.1910300604","volume":"30","author":"SW Provencher","year":"1993","unstructured":"Provencher, S. W. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 30, 672\u2013679 (1993).","journal-title":"Magn Reson Med"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-62205-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-62205-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-62205-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T02:50:13Z","timestamp":1695955813000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-62205-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,25]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["62205"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-62205-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,25]]},"assertion":[{"value":"19 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5379"}}